NCT05585320 2025-09-02
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Phase 1/2 Active not recruiting
Immuneering Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aprea Therapeutics
MedImmune LLC